Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
ISO 25539-2:2020 – Cardiovascular Implants – Vascular Stents
Requirements for Bare Metal, Drug-Eluting, and Bioresorbable Stents
Introduction to ISO 25539-2:2020
ISO 25539-2:2020 specifies requirements for vascular stents, which are tubular mesh devices implanted in arteries or veins to maintain vessel patency. These devices are used to treat coronary artery disease, peripheral arterial disease, carotid stenosis, and venous obstructions. The standard covers bare metal stents (BMS), drug-eluting stents (DES), bioresorbable vascular scaffolds (BVS), and coated stents. As the most widely referenced standard for vascular stent evaluation worldwide, ISO 25539-2 provides the regulatory framework for bench testing, preclinical assessment, and clinical performance requirements that manufacturers must satisfy for market approval.
Vascular stents are implanted in millions of patients globally each year. The third edition published in 2020 reflects decades of clinical experience and introduces updated requirements for drug-eluting coatings, absorbable materials, and more physiologically relevant test methods. The standard is recognized by regulatory bodies including the US FDA, European notified bodies, and Japanese PMDA for stent premarket approval applications.
Millions of patients receive stents annually. The 2020 third edition reflects decades of clinical experience with updated requirements for drug-eluting coatings, absorbable materials, and physiologically relevant testing.
Stent Classification and Design Attributes
The standard classifies stents by configuration, material, and intended clinical use. Balloon-expandable stents made from 316L stainless steel, cobalt-chromium, or platinum-chromium are typically used for coronary, renal, and carotid applications where precise placement is critical. Self-expanding nitinol stents are preferred for peripheral applications including the superficial femoral artery and iliac arteries where flexibility and conformability are essential. Key design attributes include scaffolding performance measured by radial strength, recoil percentage, and foreshortening, along with flexibility, conformability, radiopacity, and side-branch access capability.
| Attribute | Balloon-Expandable | Self-Expanding |
|---|---|---|
| Material | 316L SS, Co-Cr, Pt-Cr | Nitinol (Ni-Ti) |
| Deployment | Balloon inflation at 12-20 atm | Thermal shape memory release |
| Radial stiffness | High (rigid) | Moderate (flexible) |
| Chronic outward force | Low | Continuous and gentle |
| Typical applications | Coronary, renal, carotid | Peripheral SFA, iliac, carotid |
| Recoil percentage | 3-8 percent | 1-3 percent |
Balloon-expandable stents provide precise placement and high radial strength for ostial lesions, while self-expanding nitinol stents offer flexibility and conformability for peripheral arteries subjected to compression, torsion, and bending deformation.
Design Evaluation Program
The 2020 edition significantly expanded the design evaluation section. Manufacturers must establish a comprehensive evaluation plan covering dimensional verification, mechanical bench testing including radial strength measurement, fatigue testing up to 400 million cycles, crush recovery assessment, bending stiffness characterization, and flexibility testing. For drug-eluting stents, coating evaluation must address durability, particulate matter generation, drug content uniformity, and release kinetics. Corrosion assessment, MRI compatibility evaluation, and accelerated aging studies are also required, with emphasis on worst-case condition testing.
Drug-Eluting Stent Testing Requirements
| Parameter | Test Method | Acceptance Criterion |
|---|---|---|
| Drug content uniformity | HPLC analysis of 10 stents per lot | +/-10 percent of nominal dose |
| In vitro elution profile | USP apparatus under sink conditions | Specified release profile over 14-28 days |
| Particulate matter | Light obscuration and SEM | Per USP less than 788 limits |
| Coating integrity after deployment | SEM imaging crimped and expanded | No delamination or cracks larger than 25 um |
| Coating durability after fatigue | Post-fatigue SEM examination | No coating loss in articulating regions |
Stent fracture remains a clinical concern, particularly in the superficial femoral artery where stents undergo extreme mechanical deformation including axial compression, torsion, and bending. The standard requires multi-axial fatigue testing replicating these complex conditions.
The clinical evaluation of vascular stents requires well-designed studies with appropriate endpoints including target lesion revascularization, stent thrombosis rate, and binary restenosis rate. Long-term follow-up data extending to 5 and 10 years provides critical information about device safety and effectiveness over time. The standard emphasizes that clinical studies should reflect the intended patient population and include appropriate statistical analyses to support the safety and effectiveness conclusions. For drug-eluting stents, dual antiplatelet therapy duration and late thrombosis rates are important clinical considerations addressed in the evaluation framework.
Frequently Asked Questions
Q: What is the difference between ISO 25539-1 and ISO 25539-2?
A: Part 1 covers stent-grafts with fabric covering for aneurysm exclusion. Part 2 covers bare metal stents and drug-eluting stents used to maintain vessel patency without fabric covering.
A: Part 1 covers stent-grafts with fabric covering for aneurysm exclusion. Part 2 covers bare metal stents and drug-eluting stents used to maintain vessel patency without fabric covering.
Q: How are bioresorbable stents evaluated?
A: Additional testing requirements include degradation rate analysis, mechanical property evolution during the absorption process, and biocompatibility of degradation byproducts, all addressed in the 2020 edition.
A: Additional testing requirements include degradation rate analysis, mechanical property evolution during the absorption process, and biocompatibility of degradation byproducts, all addressed in the 2020 edition.
Q: What is the significance of stent recoil?
A: Stent recoil is the percentage reduction in diameter immediately after deployment. High recoil reduces the acute lumen gain and may increase the risk of restenosis over time.
A: Stent recoil is the percentage reduction in diameter immediately after deployment. High recoil reduces the acute lumen gain and may increase the risk of restenosis over time.
Q: Is MRI compatibility testing required?
A: Yes, the standard requires evaluation of MRI-related heating, displacement force, torque, and image artifact to establish safe scanning conditions for patients with implanted stents.
A: Yes, the standard requires evaluation of MRI-related heating, displacement force, torque, and image artifact to establish safe scanning conditions for patients with implanted stents.
